Skip to content
OpenCapital
Get started
Syndax Pharmaceuticals logo

Syndax Pharmaceuticals (SNDX) Q1 2026 Earnings

SNDX·Reported April 30, 2026·After market close

Syndax Pharmaceuticals reported Q1 2026 revenue of $64.9M (+223.6% YoY), missed analyst consensus of $69.8M by $4.9M. Diluted EPS came in at $-0.48 (+51.0% YoY), beat the $-0.59 consensus by $0.11.

Revenue
$64.9Mmissed by $4.9M
Consensus: $69.8M
Diluted EPS
$-0.48beat by $0.11
Consensus: $-0.59
SEC

SEC Filings

Earnings release8-K · 0001193125-26-197124
Quarterly report10-Q · 0001193125-26-197154

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Syndax Pharmaceuticals's Q1 2026 earnings report.

Syndax Pharmaceuticals (SNDX) reported Q1 2026 earnings on April 30, 2026 after market close.

Syndax Pharmaceuticals reported revenue of $64.9M and diluted EPS of $-0.48 for Q1 2026.

Revenue missed the consensus estimate of $69.8M by $4.9M. EPS beat the consensus estimate of $-0.59 by $0.11.

Compared to the same quarter a year prior, revenue grew 223.6% from $20.0M a year earlier and diluted EPS grew 51.0% from $-0.98.

You can read the 8-K earnings release (0001193125-26-197124) and the 10-Q periodic report (0001193125-26-197154) directly on SEC EDGAR. The filing index links above go to sec.gov.